After chemotherapy plus targeted therapy for advanced rectal cancer patients, the five-year survival rate is about 5% to 10%. Drugs need to be applied under the guidance of doctors.
Rectal cancer is a common malignant tumor, and the occurrence of the disease is related to a variety of factors such as bad dietary habits and heredity. When the disease develops to the late stage, multiple metastases usually occur and the patients are in poor physical condition, so there is no chance of surgical resection. Non-surgical therapies such as chemotherapy, radiotherapy and targeted therapy are often used.
Commonly used chemotherapeutic drugs include fluorouracil, capecitabine and so on; targeted drugs include bevacizumab and so on. After active treatment, advanced patients can obtain a five-year survival rate of about 5% to 10%. However, the purpose of treatment for advanced stage patients is mostly to improve the quality of life and prolong the survival period of patients.
It is recommended to consult the doctor in time for advanced rectal cancer and choose the appropriate treatment plan under the doctor’s guidance in order to prolong the survival period and improve the quality of life.